

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Better Plant Sciences Inc. (the "Issuer").

Trading Symbol: PLNT

Number of Outstanding Listed Securities: 178,473,245 common shares (plus 86,970,437 common shares reserved for issuance in the form of 88,780,437 warrants and 17,231,661 options).

Date: December 3, 2020

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

In November 2020, the Issuer announced:

- its FDA-Listed hand sanitizer gel is available for purchase on Amazon.com;
 - its majority owned subsidiary Neonmind Biosciences Inc. ("NeonMind") obtained Health Canada approval to advance its preclinical trial on psilocybin-based research;
 - it launched the new Jusu eCommerce site at getjusu.com and the Jusu product rebrand following the Company's recent acquisition of Jusu;
 - NeonMind commenced a psilocybin preclinical trial examining psilocybin as a potential treatment to promote and cause weight loss and to reduce food cravings after obtaining Health Canada approval; and
 - the launch of a customer rewards program called "Insider Rewards" for its Urban Juve skin care line.
- 2. Provide a general overview and discussion of the activities of management.**
Please see Item 1 above.
 - 3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**
Please see Item 1 above.
 - 4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

8. Describe the acquisition of new customers or loss of customers.

Please see Item 1 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Please see Item 1 above.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

During the month of October 2020, one employees' employment ceased with the Issuer and one employee was hired.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. **Provide details of any securities issued and options or warrants granted.**

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Units	6,934,245	November 4, 2020: 6,934,245 units issued pursuant to the conversion of the 6,934,245 special warrants issued on October 26, 2020. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.08 until April 26, 2021.	Not applicable.
Stock Options	500,000	November 19, 2020: 500,000 stock options granted to various employees and a consultant at an exercise price of \$0.10 per common share for a maximum period of 5 years (or earlier in accordance with the Issuer's stock option plan).	Not applicable.

(1) State aggregate proceeds and intended allocation of proceeds.

15. **Provide details of any loans to or by Related Persons.**

None.

16. **Provide details of any changes in directors, officers or committee members.**

None.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic. It has adversely affected global workforces, economies, and financial markets, triggering an economic downturn and is expected to impact many retail businesses. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak nor its effects on the Company's business or operations at this time.

The Issuer implemented travel restrictions for work related travel, and imposed self-isolation for employees with symptoms of sickness or returning from international travel. The Issuer also cancelled live multi person events such as in store pop ups and influencer events until further notice.

The Issuer is well-positioned to take advantage of the growing importance placed on physical and mental health and wellbeing, and the rising demand for high-quality, natural products that support this.

The Issuer intends to increase revenues through products that are in high and sustainable consumer demand, drawing on existing, stability-tested formulas to bring these to market under new and existing brands. It has added several hand sanitizer products to its Urban Juve brand, initiated research into topicals that may fight infectious diseases and continues with production plans for its immune boosting mushroom coffee line.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 3, 2020.

Penny White
Name of Director or Senior Officer

"Penny White"
Signature

Chief Executive Officer and
President
Official Capacity

Issuer Details Name of Issuer Better Plant Sciences Inc.	For Month End November 2020	Date of Report YY/MM/DD 20/12/03
Issuer Address Suite 200, 1238 Homer Street		
City/Province/Postal Code Vancouver, British Columbia V6B 2Y5	Issuer Fax No. N/A	Issuer Telephone No. 833.514.2677
Contact Name Penny White	Contact Position President, CEO, and Director	Contact Telephone No. 833.514.2677
Contact Email Address penny@betterplantsciences.com	Web Site Address www.betterplantsciences.com	